JAMP PILOCARPINE TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

PILOCARPINE HYDROCHLORIDE

可用日期:

JAMP PHARMA CORPORATION

ATC代码:

N07AX01

INN（国际名称）:

PILOCARPINE

剂量:

5MG

药物剂型:

TABLET

组成:

PILOCARPINE HYDROCHLORIDE 5MG

给药途径:

ORAL

每包单位数:

15G/50G

处方类型:

Prescription

治疗领域:

PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS

產品總結:

Active ingredient group (AIG) number: 0107358009; AHFS:

授权状态:

APPROVED

授权日期:

2020-12-10

产品特点

_JAMP Pilocarpine Product Monograph_
_Page 1 of 32_
PRODUCT MONOGRAPH
PR
JAMP PILOCARPINE
PILOCARPINE HYDROCHLORIDE TABLETS, USP
5 MG
CHOLINOMIMETIC AGENT
JAMP Pharma Corporation
1310, rue Nobel
Boucherville, Québec
J4B 5H3
Date of Preparation:
December 09, 2020
Submission Control No: 234963
_JAMP Pilocarpine Product Monograph_
_Page 2 of 32_
Table of Contents
PA RT I: HEALTH PROFESSIONAL INFORMATION
............................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
..................................................................................
4
ADVERSE REACTIONS
..................................................................................................
6
DRUG INTERACTIONS
................................................................................................
11
DOSAGE AND ADMINISTRATION
................................................................................
11
OVERDOSAGE
.............................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
................................................................. 13
STORAGE AND STABILITY
..........................................................................................
18
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................ 18
PART II: SCIENTIFIC INFORMATION
.....................................................................................
19
PHARMACEUTICAL INFORMATION
............................................................................
19
CLINICAL TRIALS
.........................................................................................................